Variable | Healthy controls (n = 203) | EU (n = 36) | HIV-1 TP# (n = 109) | HIV-1 LTNP# (n = 75) | pvalue |
---|---|---|---|---|---|
Male (%) | 146 (72%) | 22 (61%) | 78 (71.5%) | 50 (66.6%) | 0.59* |
Age (years) (mean ± SD) | 44.2 ± 9.9 | 46.7 ± 9.2 | 41.8 ± 8.9 | 41.6 ± 7.1 | 0.39** |
Duration of HIV-1 infection (mean ± SD) | - | - | 6.2 ± 2.7 | 18.2 ± 1.6 | < 0.0001 ##, *** |
Time span between documented infection and the onset of antiretroviral treatment (mean ± SD) | - | - | 4.8 ± 1.3 | - | - |
Plasma HIV-1 RNA (copies/ml) (median and range) | - | - | 11,808 (<50->750,000) | 267 (<50-4,600) | < 0.0001 ##, **** |
CD4+ T-cell count (cells/μl) (median and range) | - | - | 478 (6-1404) | 772 (503-2080) | < 0.0001 ##,**** |
Exposure to HIV-1 | - | 22 (61%) | 61 (56%) | 47 (62.7%) | 0.64* |
Parenteral | - | 14 (39%) | 39 (35.8%) | 22 (29.3%) | 0.53* |
Sexual | - | - | 9 (8.2%) | 6 (8%) | 0.82* |
Other |